Sagent Pharm Inc (SGNT) 21.76 $SGNT Nichi-Iko P
Post# of 273254
Posted On: 09/20/2016 1:09:06 AM
Sagent Pharm Inc (SGNT) 21.76 $SGNT
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 29, 6:58AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) ("Nichi-Iko" or "Parent"
today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent" (NASDAQ:SGNT) at $21.75 per share, net to the holder in cash, without interest, less any applicable withholding taxes. The tender offer was effected by Nichi-Iko's wholly-owned subsidiary, Shepard Vision, Inc. (the "Purchaser".
SGNT: 21.76 (+0.03)
Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Mon Aug 22, 4:51PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
SPGI: 124.68 (+1.41), TLMR: 23.26 (-0.44), SVU: 4.75 (+0.09), SCVL: 27.22 (-0.25), FCFS: 46.41 (-0.15), SGNT: 21.76 (+0.03), EGRX: 60.91 (-0.04), CHFC: 44.33 (+0.03), CSH: 42.20 (-1.33)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter
GlobeNewswire - Wed Aug 17, 4:44PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10 g (NDC 25021-163-99) Lot OXT512 (Exp. Date March 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall to the user level due to the receipt of a product complaint for a single vial containing small, dark particulate matter found within the solution after reconstitution. The particulate matter has been identified as iron oxide.
SGNT: 21.76 (+0.03)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)
GlobeNewswire - Wed Aug 10, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company" (Nasdaq:SGNT) in the United States District Court for the Northern District of Illinois on behalf of current stock holders of Sagent, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act".
SGNT: 21.76 (+0.03)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
BusinessWire - Tue Aug 09, 8:25AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent" and Shepard Vision, Inc. ("Purchaser" announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR", with respect to its proposed acquisition of Sagent Pharmaceuticals, Inc. ("Sagent"; Nasdaq: SGNT) expired effective August 8, 2016, at 11:59 p.m. (Eastern Daylight Time).
SGNT: 21.76 (+0.03)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 75.41 (-0.71), BIIB: 303.50 (-1.01), ABT: 41.68 (-0.19), JNJ: 117.66 (-0.59), GILD: 78.99 (+0.19), MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), SGNT: 21.76 (+0.03), ABBV: 62.91 (-0.36), PRTA: 61.10 (+2.67), NVS: 79.94 (+0.60)
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 01, 8:55AM CDT
Shepard Vision, Inc., a Delaware corporation (the "Purchaser" and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (the "Parent", a joint stock corporation organized under the laws of Japan, today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent", a Delaware corporation (NASDAQ: SGNT), at a price of $21.75 per Share (the "Offer Price", net to the holder in cash, without interest, less any applicable withholding taxes (the "Offer".
SGNT: 21.76 (+0.03)
Sapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors
PR Newswire - Thu Jul 28, 8:12AM CDT
Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the financial services sector, announced today that veteran software industry executive, private investor and technology consultant Andre M. Boisvert was nominated to serve as the chairman of the board of directors of Sapiens DECISION.
SPNS: 13.41 (-0.11), ISDR: 7.12 (+0.09), SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 245.29 (+0.10), SGNT: 21.76 (+0.03), TEVA: 50.70 (-1.04)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
GlobeNewswire - Mon Jun 13, 4:52PM CDT
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 (Exp. Date July 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Oxacillin for Injection, USP, 10g to the user level due to the receipt of two product complaints for small, dark particulate matter found in solution after reconstitution. The presence of particulate matter during administration has the potential to cause adverse health consequences in general patient populations.
SGNT: 21.76 (+0.03)
Sagent reports 1Q loss
Automated Insights - Tue May 03, 6:52AM CDT
SCHAUMBURG, Ill. (AP) _ Sagent Pharmaceuticals Inc. (SGNT) on Tuesday reported a loss of $5 million in its first quarter.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:30AM CDT
Company Affirms 2016 Full Year Guidance
SGNT: 21.76 (+0.03)
Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division
PR Newswire - Tue Apr 26, 7:00AM CDT
Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 8:07AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, today announced that it will release financial results for the 2016 first quarter pre-market on Tuesday, May 3, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 21.76 (+0.03)
Stock Picking Strategy to Win Every Earnings Season
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 5:27PM CDT
We are running a great screen which will help you get into winning stocks ahead of every earnings season.
CPN: 13.26 (-0.03), INGN: 59.74 (-0.47), SGNT: 21.76 (+0.03), MTN: 160.89 (+0.19), PFSW: 9.26 (+0.16)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 21.76 (+0.03)
Why Sagent Pharmaceuticals Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 13, 2:53PM CST
What: Sagent Pharmaceuticals surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker. So what: Reuters appears to have multiple...
PFE: 33.65 (-0.29), SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO(R) (Lidocaine HCl Jelly USP, 2%)
GlobeNewswire - Tue Jan 12, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO(R) (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of GLYDO by hospital experts who attended Novation's Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to organization's care and business models.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 08, 11:55AM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 66.19 (+0.37), SGNT: 21.76 (+0.03)
Timing is Crucial, Upside Analysis - Analyst Notes on Sagent Pharmaceuticals, Del Frisco's Restaurant Group, Air Transport Services Group and Edge Therapeutics
ACCESSWIRE - Thu Dec 24, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Del Frisco's Restaurant Group Inc. (NASDAQ: DFRG), Air Transport Services Group Inc. (NASDAQ: ATSG) and Edge Therapeutics Inc. (NASDAQ: EDGE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DFRG: 13.90 (-0.26), ATSG: 13.22 (-0.17), SGNT: 21.76 (+0.03), EDGE: 11.32 (-0.53)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 29, 6:58AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) ("Nichi-Iko" or "Parent"
today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent" (NASDAQ:SGNT) at $21.75 per share, net to the holder in cash, without interest, less any applicable withholding taxes. The tender offer was effected by Nichi-Iko's wholly-owned subsidiary, Shepard Vision, Inc. (the "Purchaser". SGNT: 21.76 (+0.03)
Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Mon Aug 22, 4:51PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
SPGI: 124.68 (+1.41), TLMR: 23.26 (-0.44), SVU: 4.75 (+0.09), SCVL: 27.22 (-0.25), FCFS: 46.41 (-0.15), SGNT: 21.76 (+0.03), EGRX: 60.91 (-0.04), CHFC: 44.33 (+0.03), CSH: 42.20 (-1.33)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter
GlobeNewswire - Wed Aug 17, 4:44PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10 g (NDC 25021-163-99) Lot OXT512 (Exp. Date March 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall to the user level due to the receipt of a product complaint for a single vial containing small, dark particulate matter found within the solution after reconstitution. The particulate matter has been identified as iron oxide.
SGNT: 21.76 (+0.03)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)
GlobeNewswire - Wed Aug 10, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company"
(Nasdaq:SGNT) in the United States District Court for the Northern District of Illinois on behalf of current stock holders of Sagent, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act". SGNT: 21.76 (+0.03)
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
BusinessWire - Tue Aug 09, 8:25AM CDT
Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent"
and Shepard Vision, Inc. ("Purchaser" announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR", with respect to its proposed acquisition of Sagent Pharmaceuticals, Inc. ("Sagent"; Nasdaq: SGNT) expired effective August 8, 2016, at 11:59 p.m. (Eastern Daylight Time). SGNT: 21.76 (+0.03)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 75.41 (-0.71), BIIB: 303.50 (-1.01), ABT: 41.68 (-0.19), JNJ: 117.66 (-0.59), GILD: 78.99 (+0.19), MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), SGNT: 21.76 (+0.03), ABBV: 62.91 (-0.36), PRTA: 61.10 (+2.67), NVS: 79.94 (+0.60)
Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.
BusinessWire - Mon Aug 01, 8:55AM CDT
Shepard Vision, Inc., a Delaware corporation (the "Purchaser"
and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (the "Parent", a joint stock corporation organized under the laws of Japan, today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock of Sagent Pharmaceuticals, Inc. ("Sagent", a Delaware corporation (NASDAQ: SGNT), at a price of $21.75 per Share (the "Offer Price", net to the holder in cash, without interest, less any applicable withholding taxes (the "Offer". SGNT: 21.76 (+0.03)
Sapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors
PR Newswire - Thu Jul 28, 8:12AM CDT
Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the financial services sector, announced today that veteran software industry executive, private investor and technology consultant Andre M. Boisvert was nominated to serve as the chairman of the board of directors of Sapiens DECISION.
SPNS: 13.41 (-0.11), ISDR: 7.12 (+0.09), SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 245.29 (+0.10), SGNT: 21.76 (+0.03), TEVA: 50.70 (-1.04)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
GlobeNewswire - Mon Jun 13, 4:52PM CDT
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 (Exp. Date July 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Oxacillin for Injection, USP, 10g to the user level due to the receipt of two product complaints for small, dark particulate matter found in solution after reconstitution. The presence of particulate matter during administration has the potential to cause adverse health consequences in general patient populations.
SGNT: 21.76 (+0.03)
Sagent reports 1Q loss
Automated Insights - Tue May 03, 6:52AM CDT
SCHAUMBURG, Ill. (AP) _ Sagent Pharmaceuticals Inc. (SGNT) on Tuesday reported a loss of $5 million in its first quarter.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:30AM CDT
Company Affirms 2016 Full Year Guidance
SGNT: 21.76 (+0.03)
Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division
PR Newswire - Tue Apr 26, 7:00AM CDT
Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 8:07AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, today announced that it will release financial results for the 2016 first quarter pre-market on Tuesday, May 3, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 21.76 (+0.03)
Stock Picking Strategy to Win Every Earnings Season
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 5:27PM CDT
We are running a great screen which will help you get into winning stocks ahead of every earnings season.
CPN: 13.26 (-0.03), INGN: 59.74 (-0.47), SGNT: 21.76 (+0.03), MTN: 160.89 (+0.19), PFSW: 9.26 (+0.16)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 21.76 (+0.03)
Why Sagent Pharmaceuticals Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 13, 2:53PM CST
What: Sagent Pharmaceuticals surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker. So what: Reuters appears to have multiple...
PFE: 33.65 (-0.29), SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO(R) (Lidocaine HCl Jelly USP, 2%)
GlobeNewswire - Tue Jan 12, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO(R) (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of GLYDO by hospital experts who attended Novation's Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to organization's care and business models.
SGNT: 21.76 (+0.03)
Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 08, 11:55AM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 66.19 (+0.37), SGNT: 21.76 (+0.03)
Timing is Crucial, Upside Analysis - Analyst Notes on Sagent Pharmaceuticals, Del Frisco's Restaurant Group, Air Transport Services Group and Edge Therapeutics
ACCESSWIRE - Thu Dec 24, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Del Frisco's Restaurant Group Inc. (NASDAQ: DFRG), Air Transport Services Group Inc. (NASDAQ: ATSG) and Edge Therapeutics Inc. (NASDAQ: EDGE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DFRG: 13.90 (-0.26), ATSG: 13.22 (-0.17), SGNT: 21.76 (+0.03), EDGE: 11.32 (-0.53)
(0)
(0)Scroll down for more posts ▼